Hengrui Pharma Presents 72 Studies at ASCO 2025, Demonstrating Broad Oncology Pipeline Impact
Key Insights
Hengrui Pharma showcased 15 innovative drugs across 72 research outcomes at the 2025 ASCO Annual Meeting, including 4 oral presentations and 5 rapid oral presentations.
The company presented 19 breast cancer studies featuring pyrotinib, dalpiciclib, and other agents, with pyrotinib appearing in 7 studies and dalpiciclib in 6 studies.
Camrelizumab dominated gastrointestinal cancer research with inclusion in 21 of 30 studies, reinforcing China-developed PD-1 (search) inhibitors' global presence.
Hengrui Pharma delivered a commanding presence at the 2025 ASCO Annual Meeting in Chicago, presenting research outcomes from 15 innovative drugs across 72 studies that concluded on June 3. The comprehensive showcase included 4 oral presentations, 5 rapid oral presentations, 27 poster presentations, and 36 online publications, generating widespread discussion among global oncology experts.
Breast Cancer Portfolio Shows Strong Clinical Activity
The company's breast cancer research dominated with 19 studies evaluating multiple innovative agents including pyrotinib, dalpiciclib, camrelizumab, apatinib, adebrelimab, Trastuzumab rezetecan (SHR-A1811), and SHR-2017, either as monotherapies or in combination with chemotherapies. Pyrotinib emerged as a key focus with 7 studies selected for presentation, while dalpiciclib featured in 6 studies, with both agents consistently demonstrating promising efficacy and reinforcing their established roles in breast cancer treatment.
Studies evaluating SHR-A1811 and adebrelimab were selected for rapid oral presentations, attracting considerable industry attention and highlighting the clinical potential of these emerging therapies.
Gastrointestinal Cancer Research Led by Camrelizumab
In gastrointestinal cancers, Hengrui presented 30 accepted studies featuring camrelizumab, apatinib, adebrelimab, and SHR-8068. Camrelizumab dominated this therapeutic area with inclusion in 21 of the 30 studies, demonstrating its broad therapeutic profile and potential while reinforcing its position as a key focus at ASCO. This extensive representation further solidifies the achievements of China-developed PD-1 (search) inhibitors on the global stage.
Adebrelimab, which has achieved significant breakthroughs in lung cancer in recent years, is actively expanding into new indications. Five related studies explored adebrelimab's efficacy in hepatocellular carcinoma (HCC), cholangiocarcinoma (CCA), and pancreatic cancer, representing the ongoing emergence of cutting-edge research that holds promise for improving clinical outcomes for patients with gastrointestinal tumors.
Comprehensive Oncology Portfolio Spans Multiple Tumor Types
Across diverse disease areas including lung cancer, gynecologic cancers, lymphoma, bladder cancer, head and neck cancer, melanoma, sarcoma, nasopharyngeal carcinoma, chordoma, salivary gland cancer, thymic cancer, desmoid tumors, and salivary duct carcinoma, Hengrui's innovative oncology portfolio was featured in 22 research presentations. The comprehensive portfolio included camrelizumab, apatinib, adebrelimab, pyrotinib, dalpiciclib, fluzoparib, famitinib, SHR-A1811, SHR-1501, SHR-1701, SHR-1826, SHR-A1912, and SHR-A2102.
These presentations comprised 4 oral presentations, 2 rapid oral presentations, 12 poster presentations, and 4 online publications, collectively demonstrating the company's robust R&D capabilities. Additionally, one online publication highlighted ondansetron oral soluble film, underscoring its favorable efficacy in preventing and treating chemotherapy-induced nausea and vomiting (CINV).
Sustained Global Research Leadership
For 15 consecutive years, Hengrui Pharma has consistently presented cutting-edge research at the ASCO Annual Meeting, highlighting the company's global leadership in oncology drug research and development while showcasing China's robust pharmaceutical innovation capabilities to the international academic community. The inclusion of 70 Hengrui-sponsored studies at this year's meeting reflects the strong foundation laid by the company's portfolio of 23 marketed innovative drugs and a robust pipeline of over 90 candidates currently in development.
The company remains committed to its patient-centric approach, striving to develop advanced therapeutics that support the "Healthy China" initiative and enhance clinical outcomes for patients globally.